Several in vitro and in vivo studies point to PPARα as an emerging therapeutic target for AD due to the ability of both natural (e.g., PEA) and synthetic agonists (e.g., fibrates) to modulate AD pathogenetic mechanisms and progression [136,140]. Here, PPARA is linked to Alzheimer disease.